Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Colgate-Palmolive Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.91 (market cap $29.60B), while Colgate-Palmolive Company trades at $92.58 (market cap $73.59B). The key difference: Colgate-Palmolive Company is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CL | |
|---|---|---|
Market Cap | $29.60B | $73.59B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $99.14 |
52-Week Low | $205.48 | $74.98 |
Enterprise Value | $27.56B | $80.07B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Colgate-Palmolive (CL) trades at $92.66, down 0.53% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by strength in Latin America and Asia Pacific, though North American performance remains weak. Operating cash flow remains robust at $4.20 billion for 2025. The stock is trading below the consensus price target of $99.10.
The outlook is mixed, with strong profitability and consistent earnings beats offset by high valuation multiples and domestic market challenges. The primary opportunity lies in international growth and margin expansion, while risks include intense competition and reliance on emerging markets for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
